Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | UGCG | Q16739 | 2/20 | 0.41 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1109806 | 0.89 | TSHR (0.52) | L3MBTL1TDP1TSHRALDH1A1HTT | |
| SCHEMBL25829241 | 0.87 | L3MBTL1 (0.52) | L3MBTL1TDP1TSHRALDH1A1TEAD3 | |
| SCHEMBL24006263 | 0.82 | TSHR (0.48) | L3MBTL1TDP1TSHRTEAD3HTT | |
| SCHEMBL543078 | 0.82 | ALDH1A1 (0.53) | L3MBTL1TDP1TSHRALDH1A1TEAD3 | |
| SCHEMBL25796839 | 0.81 | TSHR (0.44) | L3MBTL1TDP1TSHRALDH1A1TEAD3 | |
| SCHEMBL7106989 | 0.80 | TSHR (0.56) | L3MBTL1TDP1TSHRALDH1A1HTT | |
| SCHEMBL721274 | 0.79 | EPHX2 (0.48) | L3MBTL1TDP1TSHRALDH1A1TEAD3 | |
| SCHEMBL30937230 | 0.79 | ALDH1A1 (0.53) | L3MBTL1TDP1TSHRALDH1A1HTT | |
| SCHEMBL19040806 | 0.79 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHRTEAD3HTT | |
| SCHEMBL11145254 | 0.78 | TSHR (0.71) | TSHRALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268525-B1 | MACROCYCLIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS COMPRISING N-CYCLIC P2 MOIETIES | SCHERING CORP (US) | 2008-12-31 | — | — | EP | disclosed |
| US-6846802-B2 | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties | SCHERING CORPORATION (US) | 2005-01-25 | — | — | US | disclosed |
| CN-1441806-A | Macrocyclic NS 3-serine protease inhibitors of hepatitis C virus comprising an N-ring P2 moiety | SCHERING CORP (US) | 2003-09-10 | — | — | CN | disclosed |
| EP-1268525-A2 | MACROCYCLIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS COMPRISING N-CYCLIC P2 MOIETIES | SCHERING CORPORATION (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020107181-A1 | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties | SCHERING CORPORATION | 2002-08-08 | — | — | US | disclosed |
| WO-2001077113-A2 | MACROCYCLIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS COMPRISING N-CYCLIC P2 MOIETIES | SCHERING CORPORATION (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107181-A1 | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties | HPN, TMPRSS15, HAVCR2 | L3MBTL1 3234/4885TDP1 3335/4885TSHR 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.